Ondansetron B. Braun

Ondansetron, the active ingredient in Ondansetron B. Braun, is a 5‑HT3 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It is indicated for the prevention and treatment of nausea and vomiting caused by chemotherapy, radiotherapy, postoperative conditions, and hyperemesis gravidarum in adult patients.

GNH USA supplies Ondansetron B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide across multiple regions.

Ondansetron is used to manage nausea and vomiting associated with several clinical situations.

- Chemotherapy-induced nausea and vomiting: reduces the frequency and severity of acute and delayed nausea. - Radiotherapy-induced nausea and vomiting: prevents nausea during and after radiation treatment. - Postoperative nausea and vomiting: helps control nausea after surgery. - Hyperemesis gravidarum: provides relief from severe pregnancy‑related vomiting.

Ondansetron may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT interval prolongation. - Severe allergic reaction: anaphylaxis or angioedema. - Serotonin syndrome: rare when combined with serotonergic agents.

When using Ondansetron, certain precautions should be observed to ensure safety and efficacy.

- Cardiac monitoring: assess QT interval in patients with known cardiac risk. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before administration. - Drug interactions: avoid concurrent use with other QT‑prolonging agents. - Pregnancy: use only if benefit outweighs potential risk, as safety data are limited. - Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron can interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid): - Other QT‑prolonging drugs: increase risk of cardiac arrhythmia. - Apomorphine: may cause profound hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce ondansetron effectiveness. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): increase risk of serotonin syndrome.